Loading
companiesCompany
Synaffix (Lonza)
Licensor of the GlycoConnect site-specific ADC conjugation platform, now part of Lonza and used by dozens of ADC developers.
Overview
Synaffix, based in Oss in the Netherlands and now part of Lonza, licenses the GlycoConnect site-specific antibody-drug conjugate conjugation platform, used by dozens of ADC developers. GlycoConnect attaches payloads at the conserved Asn297 glycan to give a defined drug-to-antibody ratio, HydraSpace and toxSYN complete the platform, Lonza acquired the company in 2023 and integrated it into an end-to-end ADC service, and 2026 brought multi-target licences with Sidewinder for bispecific ADCs and with Engitix. OnCo links it to site-specific conjugation and linker chemistry, ADCs and bispecific ADCs, to ADC bioconjugation manufacturing, to Lonza, and to the idea of platform designation for linker-payloads. Whether a shared conjugation platform can earn regulatory credit that carries across products is the open question. Lonza has its own page.
Similar pages
- CompanyAbzena
Shares ADC bioconjugation manufacturing (CDMOs), Site-specific conjugation & linker chemistry.
- TechnologyPayload-linker synthesis (high-potency API)
Shares Lonza, ADC bioconjugation manufacturing (CDMOs), Antibody-drug conjugate (ADC).
- CompanyValink Therapeutics
- TermCDMO (contract development and manufacturing organisation)
- TechnologyAntibody-oligonucleotide conjugates
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- TrialA Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric
- TrialARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Shares Site-specific conjugation & linker chemistry, Antibody-drug conjugate (ADC).
- TrialA Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma